Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 1
2021 6
2022 4
2023 3
2024 5
2025 12
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.
Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J, Ye Z, Zhou R, Yu Y, Wang G, Huang N, Wu J, Rong X, Sun L, Sun H, Qiu W, Xue Y, Bin J, Liao Y, Li N, Shi M, Kim KM, Liao W. Zeng D, et al. J Immunother Cancer. 2021 Aug;9(8):e002467. doi: 10.1136/jitc-2021-002467. J Immunother Cancer. 2021. PMID: 34376552 Free PMC article. Clinical Trial.
BACKGROUND: Durable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear. ...CONCLUSIONS: Current study highlighted the promising pre …
BACKGROUND: Durable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric ca …
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A, Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Airo' Farulla L, Alessi A, Morano F, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Ann Oncol. 2025 Mar;36(3):285-296. doi: 10.1016/j.annonc.2024.11.016. Epub 2024 Dec 3. Ann Oncol. 2025. PMID: 39637944 Free article. Clinical Trial.
BACKGROUND: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit from chemotherapy. Immunotherapy may eliminate the need for chemotherapy or surgery. PATIENTS AN …
BACKGROUND: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers im …
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Chao J, et al. JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275. JAMA Oncol. 2021. PMID: 33792646 Free PMC article.
IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. ...MAIN OUTCOMES AND MEASURES: Response was assessed centrally using Response Evaluati …
IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsat …
Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.
Ji Z, Wang X, Xin J, Ma L, Zuo D, Li H, Su L, Lv X, Ge S, Zhang L, Liu Y, Zhang Y, Ding T, Deng T, Ba Y, Liu R. Ji Z, et al. J Immunother Cancer. 2024 Dec 9;12(12):e010041. doi: 10.1136/jitc-2024-010041. J Immunother Cancer. 2024. PMID: 39653554 Free PMC article. Clinical Trial.
BACKGROUND: Perioperative chemotherapy is the standard of care for patients with locally advanced gastric and gastroesophageal junction cancer. Recent evidence demonstrated the addition of programmed cell death protein 1 (PD-1) inhibitors enhanced therapeutic …
BACKGROUND: Perioperative chemotherapy is the standard of care for patients with locally advanced gastric and gastroesophageal jun …
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
Wang Y, Lu J, Chong X, Wang C, Chen X, Peng Z, Gu Y, Wang Y, Wang X, Li J, Gong J, Qi C, Yuan J, Lu Z, Lu M, Zhou J, Cao Y, Chen Y, Zhang C, Hou Z, Kou H, Shen L, Zhang X. Wang Y, et al. Signal Transduct Target Ther. 2025 Mar 14;10(1):100. doi: 10.1038/s41392-025-02193-z. Signal Transduct Target Ther. 2025. PMID: 40082418 Free PMC article. Clinical Trial.
Alpha-fetoprotein-producing gastric or gastro-esophageal junction (AFP-G/GEJ) cancer, a rare gastric cancer subtype, exhibits increased angiogenesis and more immunosuppression than non-AFP-G/GEJ cancer. The potential benefits of anti-angiogenic agents and immunot …
Alpha-fetoprotein-producing gastric or gastro-esophageal junction (AFP-G/GEJ) cancer, a rare gastric cancer subtype, exhibits …
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial.
Ma Y, Li Z, Wei C, Zhang J, Fu Q, Zhang Z, Shang C, Wang J, Wan X, Zhang B, Zhang Y, Li J, Zhang H, Bie L, Xia Q, Luo S, Li N. Ma Y, et al. Gastric Cancer. 2025 Jul;28(4):652-661. doi: 10.1007/s10120-025-01606-w. Epub 2025 Apr 4. Gastric Cancer. 2025. PMID: 40184004 Free PMC article. Clinical Trial.
BACKGROUND: The impact of neoadjuvant combined chemotherapy, immunotherapy, and targeted therapy on pathologic responses and survival outcomes in HER2-positive locally advanced gastric cancer remains unclear. PATIENTS AND METHODS: In this single-arm, phase …
BACKGROUND: The impact of neoadjuvant combined chemotherapy, immunotherapy, and targeted therapy on pathologic responses and survival …
Addition of immunotherapy to perioperative chemotherapy for resectable gastric and gastroesophageal junction cancer: a meta-analysis of phase 2/3 trials.
Lin Y, Liao Y, Shen J. Lin Y, et al. Front Immunol. 2025 Nov 19;16:1692336. doi: 10.3389/fimmu.2025.1692336. eCollection 2025. Front Immunol. 2025. PMID: 41346601 Free PMC article.
BACKGROUND: The integration of immune checkpoint inhibitors (ICIs) with perioperative chemotherapy (CT) has become a major focus of clinical research in resectable gastric or gastroesophageal junction (G/GEJ) cancer. Recent phase 2 and 3 trials have reported dispara …
BACKGROUND: The integration of immune checkpoint inhibitors (ICIs) with perioperative chemotherapy (CT) has become a major focus of clinical …
Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol.
Chen B, Zhao J, Lv H, Xu W, Wang J, Nie C, He Y, Zhang B, Huang J, Liu Y, Ma F, Zhang H, Guo Y, Liu Y, Li P, Chen X, Chen X. Chen B, et al. BMJ Open. 2025 Sep 26;15(9):e100241. doi: 10.1136/bmjopen-2025-100241. BMJ Open. 2025. PMID: 41005780 Free PMC article.
INTRODUCTION: Systemic therapies for advanced gastric cancer (GC), including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. ...The dosing regimen during the dose escalation phase will include three differen …
INTRODUCTION: Systemic therapies for advanced gastric cancer (GC), including chemotherapy, targeted therapy and immunothera …
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing.
Lavacchi D, Fancelli S, Buttitta E, Vannini G, Guidolin A, Winchler C, Caliman E, Vannini A, Giommoni E, Brugia M, Cianchi F, Pillozzi S, Roviello G, Antonuzzo L. Lavacchi D, et al. Int J Mol Sci. 2023 Mar 2;24(5):4877. doi: 10.3390/ijms24054877. Int J Mol Sci. 2023. PMID: 36902306 Free PMC article. Review.
In this review, we summarize the evidence of potential tailored approaches in perioperative treatment of G/GEJ cancer, with a special focus on patients with human epidermal growth factor receptor-2(HER2)-positive and microsatellite instability-high (MSI-H) tumors. I …
In this review, we summarize the evidence of potential tailored approaches in perioperative treatment of G/GEJ cancer, with a special focus …
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y, Li D, Zhuang J, Li Z, Xia Q, Li Z, Yu J, Wang J, Zhang Y, Li K, Xu S, Li S, Ma P, Cao Y, Liu C, Xu C, Liu Z, Wei J, Zhang C, Qiao L, Gao X, Hou Z, Liu C, Zheng R, Wang D, Liu Y. Zhao Y, et al. Clin Transl Med. 2024 May;14(5):e1674. doi: 10.1002/ctm2.1674. Clin Transl Med. 2024. PMID: 38685486 Free PMC article. Clinical Trial.
BACKGROUND: The current standard of care for locally advanced gastric cancer (GC) involves neoadjuvant chemotherapy followed by radical surgery. Recently, neoadjuvant treatment for this condition has involved the exploration of immunotherapy plus chemotherapy …
BACKGROUND: The current standard of care for locally advanced gastric cancer (GC) involves neoadjuvant chemotherapy followed b …
33 results